Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIS43LS Phase 1 for Malaria Prevention
NCT04206332Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2020
- Primary completion
- Feb 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of CIS43LS in malaria (17 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms at 7 days, Number of Participants Reporting Systemic Reactogenicity Signs and Symptoms at 7 days and 4 more. Started Jan 2020; status: completed.
02
Drugs
CIS43LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT04206332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206332.